Raffa, Robert B. and Westfield, Gerwin (2019) More Rapid Sleep Onset with Lingual-Spray vs Oral-Tablet Delivery Zolpidem. Pharmacology & Pharmacy, 10 (07). pp. 329-342. ISSN 2157-9423
![[thumbnail of PP_2019073114471362.pdf]](http://note.send2pub.com/style/images/fileicons/text.png)
PP_2019073114471362.pdf - Published Version
Download (2MB)
Abstract
Insomnia and related sleep disorders (somnipathies) affect a large segment of the population, and result in a significant negative impact on quality of life and reduced or lost productivity. The speed of sleep onset is a critical characteristic of successful pharmacotherapeutic intervention for insomnia. Zolpidem, a non-benzodiazepine benzodiazepine receptor agonist (nBzRA) is widely used to treat insomnia. Although not itself a benzodiazepine (BZD), zolpidem has high binding affinity for the benzodiazepine receptor, which acts as a positive allosteric modulator of the GABAA receptor complex. It therefore increases the neuronal transmembrane influx of Cl- ions, thereby decreasing neuronal excitability and promoting sleep. In this four-way crossover, dose-ranging, multiple-treatment study, a lingual spray formulation of zolpidem was safe and well-tolerated and yielded more rapid pharmacokinetics (mean plasma concentration) and efficacy (visual analog scale and digit symbol substitution test) compared to oral tablets.
Item Type: | Article |
---|---|
Subjects: | STM One > Chemical Science |
Depositing User: | Unnamed user with email support@stmone.org |
Date Deposited: | 17 Feb 2023 10:25 |
Last Modified: | 26 Apr 2025 08:17 |
URI: | http://note.send2pub.com/id/eprint/308 |